瑞银下调开拓药业－B(09939.HK)目标价至72.2元评级「买入」

AAFN2021-11-01

瑞银发表研究报告指，默沙东药厂近日公布旗下口服候选药物莫努匹韦(molnupiravir)第三期临床试验结果，数据表现正面，该产品可用於对抗新冠病毒，连同上月公司提交的紧急使用授权申请，预期莫努匹韦有机会成为全球首款获批用於治疗新冠的口服药物。报告指出，莫努匹韦研究进度超越开拓药业的同类产品普克鲁胺(proxalutamide)，预期普克鲁胺第三期中期数据可能要到12月才发布，但认为投资者对...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Jocky0o0
2021-11-01
Jocky0o0
???

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2180027861?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","is_english":false,"pubTime":"2021-11-01 11:29","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2180027861","market":"us","top_or_hot":-1,"title":"瑞银下调开拓药业－B(09939.HK)目标价至72.2元  评级「买入」","media":"AAFN","content":"<div>\n<p>瑞银发表研究报告指，默沙东药厂近日公布旗下口服候选药物莫努匹韦(molnupiravir)第三期临床试验结果，数据表现正面，该产品可用於对抗新冠病毒，连同上月公司提交的紧急使用授权申请，预期莫努匹韦有机会成为全球首款获批用於治疗新冠的口服药物。报告指出，莫努匹韦研究进度超越开拓药业  的同类产品普克鲁胺(proxalutamide)，预期普克鲁胺第三期中期数据可能要到12月才发布，但认为投资者对...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1139283&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞银下调开拓药业－B(09939.HK)目标价至72.2元  评级「买入」</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞银下调开拓药业－B(09939.HK)目标价至72.2元  评级「买入」\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 11:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1139283&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>瑞银发表研究报告指，默沙东药厂近日公布旗下口服候选药物莫努匹韦(molnupiravir)第三期临床试验结果，数据表现正面，该产品可用於对抗新冠病毒，连同上月公司提交的紧急使用授权申请，预期莫努匹韦有机会成为全球首款获批用於治疗新冠的口服药物。报告指出，莫努匹韦研究进度超越开拓药业  的同类产品普克鲁胺(proxalutamide)，预期普克鲁胺第三期中期数据可能要到12月才发布，但认为投资者对...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1139283&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1139283&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2180027861","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2180027861","pubTimestamp":1635737349,"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"瑞银发表研究报告指，默沙东药厂近日公布旗下口服候选药物莫努匹韦第三期临床试验结果，数据表现正面，该产品可用於对抗新冠病毒，连同上月公司提交的紧急使用授权申请，预期莫努匹韦有机会成为全球首款获批用於治疗新冠的口服药物。瑞银下调普克鲁胺的销售预测，并更新对公司的盈利预测，料2021年每股亏损达1.45元人民币，2022至2023年每股盈利预测分别下调25%及26%至16.85元人民币及9.05元人民币，目标价由92.3元降至72.2元，维持「买入」评级。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09939":"开拓药业-B"},"translate_title":"UBS lowered the target price of Kaituo Pharmaceutical-B (09939. HK) to 72.2 yuan rating \"buy\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1},"content_text":"瑞银发表研究报告指，默沙东药厂近日公布旗下口服候选药物莫努匹韦(molnupiravir)第三期临床试验结果，数据表现正面，该产品可用於对抗新冠病毒，连同上月公司提交的紧急使用授权申请，预期莫努匹韦有机会成为全球首款获批用於治疗新冠的口服药物。报告指出，莫努匹韦研究进度超越开拓药业  的同类产品普克鲁胺(proxalutamide)，预期普克鲁胺第三期中期数据可能要到12月才发布，但认为投资者对莫努匹韦的潜在威胁反应过度，或忽视开拓药业的普克鲁胺具有潜在更好疗效和安全性，以及更广泛的患者覆盖范围。瑞银下调普克鲁胺的销售预测，并更新对公司的盈利预测，料2021年每股亏损达1.45元人民币，2022至2023年每股盈利预测分别下调25%及26%至16.85元人民币及9.05元人民币，目标价由92.3元降至72.2元，维持「买入」评级。(gc/t)~阿思达克财经新闻网址: www.aastocks.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":849831172,"gmtCreate":1635740654340,"gmtModify":1635740654340,"author":{"id":"3555200764688990","authorId":"3555200764688990","name":"Jocky0o0","avatar":"https://static.tigerbbs.com/c5ae67192ca7a70ee5d76eb1134c140c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849831172","repostId":2180027861,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2180027861"}

瑞银下调开拓药业－B(09939.HK)目标价至72.2元 评级「买入」

精彩评论

瑞银下调开拓药业－B(09939.HK)目标价至72.2元评级「买入」